C*X
2 楼
是的，下看80
s*r
3 楼
老李调转方向了？？
f*y
4 楼
雷。。。。上周出水没卖，亏肥了
C*X
5 楼
回调而已
【在 s******r 的大作中提到】
: 老李调转方向了？？
【在 s******r 的大作中提到】
: 老李调转方向了？？
f*y
6 楼
一月的put先留着，话说这家想砸下去也很难
【在 f********y 的大作中提到】
: 雷。。。。上周出水没卖，亏肥了
【在 f********y 的大作中提到】
: 雷。。。。上周出水没卖，亏肥了
s*r
7 楼
20%的会跳，你也太狠了。有没有时间线啊，我上次又冒着被老婆买的风险买回了一些
【在 C**X 的大作中提到】
: 回调而已
【在 C**X 的大作中提到】
: 回调而已
C*X
8 楼
怎么被老婆买？ 你当鸭子？
【在 s******r 的大作中提到】
: 20%的会跳，你也太狠了。有没有时间线啊，我上次又冒着被老婆买的风险买回了一些
【在 s******r 的大作中提到】
: 20%的会跳，你也太狠了。有没有时间线啊，我上次又冒着被老婆买的风险买回了一些
l*u
9 楼
老李目光入菊。
一些
【在 C**X 的大作中提到】
: 怎么被老婆买？ 你当鸭子？
一些
【在 C**X 的大作中提到】
: 怎么被老婆买？ 你当鸭子？
s*r
10 楼
骂，typo是古板标准操作程序，老id这点都悟不出来
【在 C**X 的大作中提到】
: 怎么被老婆买？ 你当鸭子？
【在 C**X 的大作中提到】
: 怎么被老婆买？ 你当鸭子？
C*X
11 楼
尼玛，以为你家真的如此浪漫，还有这些游戏。
【在 s******r 的大作中提到】
: 骂，typo是古板标准操作程序，老id这点都悟不出来
【在 s******r 的大作中提到】
: 骂，typo是古板标准操作程序，老id这点都悟不出来
Q*T
12 楼
ABBV消息出来前不会再涨了，但也不觉得会下100。震荡吧。
就算abbv通过了，也只是暂时dip。大盘稳了以后会一直升吧。
就算abbv通过了，也只是暂时dip。大盘稳了以后会一直升吧。
k*1
13 楼
又快到捡钱的位置了。。太好了
f*y
14 楼
除了ABBV之外，ACHN年底会出一些重要数据，如果他家的combo是best in class，
GILD也会受影响。
【在 f******y 的大作中提到】
: 突破失败，要大幅回调？
GILD也会受影响。
【在 f******y 的大作中提到】
: 突破失败，要大幅回调？
f*y
15 楼
For gilead investors:
HCV is huge to the company, and competition is still there. That is why
gilead is keep doing 1st gen, 2nd gen, 3rd gen.. and are keen to push them
to the market asap. They bought this voucher just to have next gen hit
market 6 month earlier.
++++++++++++++++++++++++++
For the first time since the FDA began a voucher program several years ago
to encourage development of drugs to treat neglected tropical diseases, a
drug maker has sold a voucher to another company. And the deal may help the
pharmaceutical industry ballpark the value of these vouchers.
In a brief statement, Knight Therapeutics says Gilead Sciences agGILD -0.67%
reed to pay $125 million for a voucher that the small Canadian drug maker
obtained from the FDA last March. The agency awarded the voucher at the same
time it approved Impavido, a medication that Knight developed to treat
leishmaniasis, a parasitic disease spread by sand flies.
The program has generated interest, because a drug maker that develops a
treatment for a qualifying tropical disease receives a voucher for an FDA
priority review for another medicine, which means the agency would be
obligated to review the medicine in six months, instead of the standard 10
months.
HCV is huge to the company, and competition is still there. That is why
gilead is keep doing 1st gen, 2nd gen, 3rd gen.. and are keen to push them
to the market asap. They bought this voucher just to have next gen hit
market 6 month earlier.
++++++++++++++++++++++++++
For the first time since the FDA began a voucher program several years ago
to encourage development of drugs to treat neglected tropical diseases, a
drug maker has sold a voucher to another company. And the deal may help the
pharmaceutical industry ballpark the value of these vouchers.
In a brief statement, Knight Therapeutics says Gilead Sciences agGILD -0.67%
reed to pay $125 million for a voucher that the small Canadian drug maker
obtained from the FDA last March. The agency awarded the voucher at the same
time it approved Impavido, a medication that Knight developed to treat
leishmaniasis, a parasitic disease spread by sand flies.
The program has generated interest, because a drug maker that develops a
treatment for a qualifying tropical disease receives a voucher for an FDA
priority review for another medicine, which means the agency would be
obligated to review the medicine in six months, instead of the standard 10
months.
C*X
16 楼
不错啊， 等80
【在 C**X 的大作中提到】
: 是的，下看80
【在 C**X 的大作中提到】
: 是的，下看80
相关阅读